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Opioids such as morphine numb pain but often concomitantly induce itch. Liu et al. (2011) now
separate the sensation of itch from opioid-induced analgesia, showing that in a subset of spinal
neurons, morphine directly induces itch by signaling through a heteromer of opioid- and itch-medi-
ating G protein-coupled receptors.Itch, or pruritus, is defined as an un-
pleasant sensation that elicits the desire
or reflex to scratch (Ikoma et al., 2006).
Itch occurs under many pathological con-
ditions, such as atopic dermatitis, and is
a common side effect of many drugs, in-
cluding antibiotics, antifungal drugs, and
narcotic pain medications (Reich et al.,
2009). For example, the malaria drug
chloroquine induces itch by acting on
peripheral sensory neurons via a G
protein-coupled receptor, MrgprA3 (Liu
et al., 2009). Another example is opioid-
induced itch, which is most severe when
opioids are administered directly into the
spinal column via an epidural injection.
Spinal opioid-induced itch has been
assumed to arise as a consequence of
pain inhibition, but the underlying mecha-
nism has been largely unknown. In this
issue of Cell, a study by Liu et al. provides
compelling evidence that spinal opioid-
induced itch is evoked independently of
opioid-induced analgesia by signaling
through an opioid receptor splice isoform
expressed in itch-mediating spinal neu-
rons (Liu et al., 2011).The distinct sensations of itch and pain
are evoked by different stimuli and induce
discrete responses (scratching versus
withdrawal). However, interactions be-
tween these two sensations are well
known; various types of noxious stimuli
are able to inhibit itch, and inhibition of
pain may evoke itch (Ikoma et al., 2006).
It has been postulated that pain signals
have a dominant inhibitory effect on
itch signals. This selectivity model is sup-
ported by recent studies reporting attenu-
ated pain and enhanced itch behaviors
in mice whose neurotransmission is in-
activated in subsets of nociceptive sen-
sory neurons (Patel and Dong, 2010). As
the selectivity model predicts, opioid-
induced itch has been thought to arise
indirectly as a consequence of opioid-
induced analgesia.
The new study by Liu et al. explores
the molecular basis of morphine-induced
scratching (MIS) and analgesia (MIA) in
mice. Previous experiments had estab-
lished that both MIS and MIA are medi-
ated by m-opioid receptor (MOR) (Loh
et al., 1998; Matthes et al., 1996). Themouse Oprm gene encodes many splice
isoforms of MOR (Pan, 2005). Liu and col-
leagues used exon-specific siRNA knock-
down in vivo and identified MOR1D and
MOR1 isoforms to be specifically required
for itch and analgesia, respectively.
MOR1D is coexpressed with the gastrin-
releasing peptide receptor (GRPR), a G
protein-coupled receptor that marks
spinal cord neurons required for the
sensation of itch (Sun and Chen, 2007;
Sun et al., 2009). Both pharmacological
and genetic knockdown of GRPR resulted
in specific attenuation of MIS without
affecting MIA (Figure 1). The authors
show that MOR1D and GRPR physically
interact. Upon further investigation, they
provide functional evidence that these
two receptors cross-activate in only one
direction: MOR1D activation by morphine
results in GRPR activation, but not
vice versa. Providing potential therapeutic
insight, Liu and colleagues show that
a unique C-terminal peptide of MOR1D
attached to a plasma membrane-perme-
ating signal competes with endogenous
MOR1D for physical interaction with, October 14, 2011 ª2011 Elsevier Inc. 261
Figure 1. Spinal Opioid-Induced Analgesia and Itch Are Distinctly
Mediated by Two Splice Isoforms of m-Opioid Receptor
Model for spinal opioid-induced analgesia and itch. Two m-opioid receptor
(MOR) splice isoforms (MOR1 and MOR1D) have distinct C termini, are ex-
pressed in mutually exclusive subsets of spinal cord neurons, and mediate
spinal opioid-induced analgesia and itch, respectively. Gastrin-releasing
peptide receptor (GRPR) is a G protein-coupled receptor, which marks spinal
cord neurons required for itch.
(A) MOR1, the major MOR isoform, is not coexpressed with GRPR and
mediates spinal opioid-induced analgesia.
(B) MOR1D is coexpressed with GRPR, and activation of MOR1D stimulates
GRPR to mediate spinal opioid-induced itch.GRPR. Spinal administration
of this synthetic peptide at-
tenuates MIS without af-
fecting MIA, indicating that
MOR1D-GRPR cross-activa-
tion is required for spinal
opioid-induced itch.
Liu et al. convincingly dem-
onstrate a direct role of opioid
receptors in itch signaling but
cannot exclude the possibility
that other indirect mecha-
nisms also mediate opioid-
induced itch. The new insights
gained from this study about
the relationship between pain
and itch raise important
questions. What is the mech-
anism behind the unidirec-
tional cross-activation of
the MOR1D-GRPR complex;
what is the role of MOR1D in
other locations, such as in
the peripheral nervous system
and in the brain; and why is
opioid signaling linked to
itch? Is the itch-inducing
pathway only relevant at clin-
ical but not endogenous
doses of opioids? One possi-
bility, as proposed by the au-
thors, is that the unpleasant
opioid-associated itchingsensationmight serve as awarning signal,
protecting the body from potential opiate
overdose (due to external sources or
metabolic disorders that cause increased
endogenous opioids). However, this
model does not seem in accord with the
antipruritic effect of k-opioids (Ikoma
et al., 2006), and it is not clear how a feed-
back signal from itch would benefit meta-
bolic disorders. In vivo comparisons
between MOR1D and MOR1 sensitivities
to physiological concentration of opioids
may shed light on the physiological rele-
vance of the MOR1D pathway. MOR1D
isoform-specific conditional knockouts262 Cell 147, October 14, 2011 ª2011 Elseviwould also be very valuable for studies
in pruritus and beyond.
This study offers the possibility to
develop a novel therapeutic strategy to
specifically attenuate itch without af-
fecting the analgesic efficacy of opioids.
When opioids are spinally administered,
60%–90% of patients are affected by
itch. Current therapeutics against opioid-
induced itch are mostly opioid receptor
antagonists that also attenuate analgesic
effect (Reich et al., 2009). The authors
propose that blocking MOR1D-GRPR
heterodimerization is a highly specific
way to attenuate opioid-induced itch.er Inc.Indeed, they demonstrate
the viability of this approach
using a synthetic peptide
administered intrathecally.
This is a logical albeit chal-
lenging strategy, as very few
approved drugs specifically
target protein-protein interac-
tions. As an alternative, many
of the molecular components
in the opioid-induced itch
pathway, including GRPR,
PLCb, and IP3R3, may be ad-
ditional candidate targets for
specifically attenuating itch.
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